Alternatives to Generate Biomedicines

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Xaira Therapeutics pairs causal AI perturbation models X-Cell and X-Design with agentic and robotic labs to find, design, and validate new

PepGLAD generates full-atom peptide structures and sequences together, conditioned on a target protein binding pocket, via geometric latent diffusion.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Physics-based molecular simulation with AI for drug discovery and materials design.

Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery with weekly wet lab readouts and a clinical-stage pipeline.

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Automated cloud lab for protein validation — binding, expression and thermostability assays with data back in as little as 3 days

AI-first biotech pairing Proton's machine-learning medicinal chemistry with synthesis-aware molecule design.

Novaflow is an AI data analyst that turns raw biology data into publication-ready figures and methods, no terminal required.

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

AI enzyme design for pharma manufacturing and life science tools, validated in Pando's own ultra-high-throughput screening lab.

A research-stage AI platform for discovering neurotherapeutics that act on neural circuits across multiple disorders.

Zeon Systems turns a plain-language experiment prompt into a robot-executed wet lab protocol, with a world-model preview before anything moves.

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.